Dose range evaluation of mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3295-3304

  Louie, Arnold ^a   Stein, Daniel S ^b   Zack, Julia Z ^b,c   Liu, Weiguo ^a   Conde, Haley ^a   Fregeau, Christine ^a   VanScoy, Brian D ^a   Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; EFUNGUMAB; EFUNGUMAB C28Y VARIANT; HEAT SHOCK PROTEIN 90; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; INVASIVE CANDIDIASIS; KIDNEY CELL CULTURE; LIVER CELL CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE RESEARCH; SPLEEN; TREATMENT DURATION;

AMPHOTERICIN B; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; CANDIDIASIS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS;

EID: 79959256586     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01324-10     Document Type: Article

References (15)

1. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard, 3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Gudlaugsson, O., et al. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177.
3. Kullberg, B. J., et al. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet 366:1435-1442. (Pubitemid 41483809)
4. Matthews, R. C., et al. 1998. Stress proteins in fungal diseases. Med. Mycol. 36(Suppl.):45-51.
5. Matthews, R. C., et al. 2003. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47:2208-2216.
6. Matthews, R. C., J. P. Burnie, and S. Tabaqchali. 1984. Immmunoblot analysis of the serological response in systemic candidosis. Lancet ii:1415-1418. (Pubitemid 15175118)
7. Matthews, R. C., J. P. Burnie, and S. Tabaqchali. 1987. Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans. J. Clin. Microbiol. 25:230-237.
8. McNeil, M. M., et al. 2001. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. 33:641-647.
9. Mora-Duarte, J., et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
10. Pachl, J., et al. 2006. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. 42:1404-1413.
11. Pappas, P. G., et al. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893.
12. Rex J. H., et al. 2003. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36:1221-1228.
13. Rex, J. H., et al. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
14. Swoboda, R. K., et al. 1995. Structure and regulation of the HSP90 gene from the pathogenic fungus Candida albicans. Infect. Immun. 63:4506-4514.
15. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.